New drug cocktail shows promise against aggressive stomach cancer

NCT ID NCT04661150

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will receive either the standard combo or the standard plus atezolizumab. The main goal is to see if the new combination leads to more complete tumor disappearance at the time of surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, 100142, China
First Hospital of China Medical University

Shenyang, 110001, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Liaoning Provincial Cancer Hospital

Shengyang, 110042, China
Nanfang Hospital, Southern Medical University

Guangzhou, 510515, China
Tianjin Medical University Cancer Institute & Hospital

Tianjing, 300060, China
West China Hospital, Sichuan University

Chengdu, 610041, China
Zhongshan Hospital Fudan University

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.